Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ashtead maintains guidance after record year so far

(Sharecast News) - Equipment rental firm Ashtead said it expects full-year results to rise in line with previous guidance, after a record performance over the first nine months of the year. The company, which operates under the Sunbelt Rentals brand, said rental revenues are expected to rise by 3-5% for the year ending 31 March.

However, rental revenue growth in Canada - which accounts for just under a tenth of sales - is now expected to be 9-13%, down from earlier estimates of 15-19%.

Group revenues over nine months to 31 January were flat on last year at $8.26bn, with rental revenues growing 5% to $7.65bn, though growth was limited to just 1% in the third quarter.

Ashtead said the strength of mega projects and hurricane response efforts in North America managed to offset the lower activity levels in local commercial construction markets, where demand has been affected by the continued high interest rates.

"However, underlying demand continues to be strong and we expect this segment to recover as interest rates stabilise," it said.

Adjusted EBITDA for the first three quarters combined totalled $3.87bn, up 3% on the year before.

"We are in a position of strength, with the operational flexibility and financial capacity to take advantage of the ongoing structural growth opportunities we see for the business and enhance returns to shareholders as we follow our Sunbelt 4.0 plan," said chief executive Brendan Horgan.

"We expect full-year results in line with our previous expectations and the board looks to the future with confidence."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.